Table 1.
MicroRNAs Aberrantly Expressed in Tumors
| Tumor Type | Upregulated MicroRNA | Downregulated MicroRNA | Target |
|---|---|---|---|
| CLL5–7 | miR-29, miR-181 | TCL1 | |
| miR-155 | |||
| miR-15a, miR-16-1 | BCL2 | ||
| AML8 | miR-29 | MCL1 | |
| DNMT | |||
| Lymphoma9–15 | miR-155 | ||
| miR-17-92 | PTEN, BIM,E2F1 | ||
| miR-106b-25 | E2F1 | ||
| MM16,17 | miR-21 | ||
| miR-19a, miR-19b | SOCS1 | ||
| Breast cancer18–27 | miR-21 | PTEN, PDCD4, TPM1 | |
| miR-125b | HER2, HER3 | ||
| miR-205 | HER3 | ||
| miR-10b (associated with metastasis) | HOXD10 | ||
| miR-373 | |||
| miR-200 | ZEB | ||
| Lung cancer28–32 | let-7 | RAS, HMGA2, C-MYC | |
| miR-155 | |||
| HCC28,34,35 | miR-122a | Cyclin G1 | |
| miR-221 | p27 | ||
| miR-34a | MET |
Abbreviations: CLL, chronic lymphocytic leukemia; AML, acute myelocytic leukemia; MM, multiple myeloma; HCC, hepatocellular carcinoma.